Benzyl sibutramine Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Vendor-neutral scientific reference catalog record for benzyl sibutramine.

Sibutramine analogue compound Reference needs_revision Best effort · source review pending

Also known as: Benzylsibutramine, 11-Desisobutyl-11-benzylsibutramine, Desisobutyl-benzylsibutramine

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

Not standardized / source review pending

Best-Effort Research Profile

Benzyl sibutramine is a small-molecule sibutramine analogue in which a benzyl group replaces sibutramine's isobutyl substituent. It was first structurally identified in a weight-loss supplement by liquid chromatography–mass spectrometry, tandem mass spectrometry, and nuclear magnetic resonance. No approved therapeutic use or established clinical dosing regimen was identified in the authoritative sources reviewed.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Reported Research Effects

In a 2025 FDA-authored in vitro and in silico target-binding study, benzyl sibutramine was among the benzyl analogues showing weaker binding across nearly all evaluated targets than several other sibutramine analogues; reported binding constants for benzyl and formyl analogues ranged from 0.447 to greater than 10 micromolar.
The available evidence does not establish clinical efficacy, clinical pharmacokinetics, or human safety for benzyl sibutramine.

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Notes

The compound was reported in 2013 after isolation from a weight-loss supplement collected during an FDA import operation. Structural elucidation used high-resolution mass spectrometry, tandem mass spectrometry, and NMR. FDA notifications in 2025 and 2026 document its detection as an undeclared ingredient in adulterated weight-loss products. No reliable authoritative source located in this review provides a validated half-life, onset, solubility profile, storage specification, or evidence-backed human administration regimen.

Supplementary research context only. Not medical advice or a treatment recommendation.

Registry Identifiers

CAS RN 1446140-91-5; PubChem CID 112500541; FDA UNII JQZ2PMN6BP; EPA DSSTox ID DTXSID301316283; molecular formula C20H24ClN; molecular weight 313.864 g/mol; InChIKey LHZSUCMYGFCXNC-UHFFFAOYSA-N; IUPAC name 1-[1-(4-chlorophenyl)cyclobutyl]-N,N-dimethyl-2-phenylethanamine

Source-Backed Observations

NCATS identifies the substance as racemic with one undefined stereocenter. The compound is documented primarily as an analytically detected sibutramine analogue in adulterated weight-loss products rather than as an approved medicine or established clinical research agent.

Reflects published research. Educational reference — not a recommendation for use.

Sources Under Review

Benzylsibutramine | CID 112500541
https://pubchem.ncbi.nlm.nih.gov/compound/Benzylsibutramine (accessed 2026-09-15)

Rapid screening and structural elucidation of a novel sibutramine analogue in a weight loss supplement: 11-desisobutyl-11-benzylsibutramine
https://pubmed.ncbi.nlm.nih.gov/23739298/ (accessed 2026-09-15)

Safety pharmacology of sibutramine analogues evaluated by in silico and in vitro biological target screening
https://pubmed.ncbi.nlm.nih.gov/40683513/ (accessed 2026-09-15)

FATZorb may be harmful due to hidden drug ingredients
https://www.fda.gov/drugs/medication-health-fraud-notifications/fatzorb-may-be-harmful-due-hidden-drug-ingredients (accessed 2026-09-15)

Esbelta Intense Loss may be harmful due to hidden ingredients
https://www.fda.gov/drugs/medication-health-fraud-notifications/esbelta-intense-loss-may-be-harmful-due-hidden-ingredients (accessed 2026-09-15)

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.